Increasing Survival in Stage III NSCLC: Optimizing Care and Addressing New Clinical Challenges

In this online CME/MOC-certified program, experts discuss recent advances in the use of immunotherapy to optimize outcomes in patients with stage III NSCLC. Watch the on-demand Webcast and download the slides from a dynamic CCO symposium at the 2019 SITC Annual Meeting to learn more about how to integrate immunotherapies into your clinical practice.
Roy S. Herbst, MD, PhD
Melissa L. Johnson, MD

Downloadable Slideset

Download this slideset for expert perspectives on the optimal use of immune checkpoint inhibitors for stage III NSCLC in the clinic today, as well as a look at emerging approaches with these agents in this and earlier stages of disease.

Roy S. Herbst, MD, PhD Melissa L. Johnson, MD Released: November 8, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?